{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-119847","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.725615+00:00","generated_at":"2026-05-21T08:00:30.901849+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Codexis Q1 revenue drops to $7.5M from $17.1M; net loss widens to $20.7M","bullets":["Revenue $7.5M vs $17.1M in Q1 2024; decline due to $6M one-time Roche license and large orders in prior year.","Net loss $20.7M ($0.25/share) vs $11.5M ($0.16/share) in Q1 2024; R&D expenses up to $12.9M.","Cash $59.8M; expects to fund operations through positive cash flow by end 2026.","Reiterates FY 2025 revenue guidance of $64M-$68M; secured first revenue contract for ECO Synthesis manufacturing.","Appointed Christos Richards and Cynthia Collins to board; Arthur Levin to Strategic Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-119847","json":"https://secwatch.observer/filing/0001193125-25-119847.json","markdown":"https://secwatch.observer/filing/0001193125-25-119847.md","text":"https://secwatch.observer/filing/0001193125-25-119847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000119312525119847/0001193125-25-119847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000119312525119847/d949323d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:00:30.901849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}